RBC Capital Reiterates Outperform Rating on Definium Therapeutics Inc (DFTX), sees favorable set up

May 8, 2026 6:32 AM

RBC Capital analyst Brian Ambrahams reiterated an Outperform rating and $36.00 price target on Definium Therapeutics Inc (NASDAQ: DFTX).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found